Company’s 36-month beta value is 1.01.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 6 as “hold,” and 0 as “sell.”
The public float for RXRX is 305.89M, and currently, short sellers hold a 28.25% ratio of that floaft. The average trading volume of RXRX on April 07, 2025 was 23.24M shares.
RXRX) stock’s latest price update
The stock of Recursion Pharmaceuticals Inc (NASDAQ: RXRX) has decreased by -11.85 when compared to last closing price of 4.81. Despite this, the company has experienced a -27.02% fall in its stock price over the last five trading sessions. fool.com reported 2025-04-03 that Shares of early-stage biotech stocks, including Biohaven (BHVN -6.50%), Recursion Pharmaceuticals (RXRX -4.92%), and CRISPR Therapeutics (CRSP -2.05%), plunged in March, with the stocks down 35.3%, 29.6%, and 22.5%, respectively, according to data from S&P Global Market Intelligence.
RXRX’s Market Performance
Recursion Pharmaceuticals Inc (RXRX) has experienced a -27.02% fall in stock performance for the past week, with a -32.05% drop in the past month, and a -41.19% drop in the past quarter. The volatility ratio for the week is 8.69%, and the volatility levels for the past 30 days are at 7.13% for RXRX. The simple moving average for the last 20 days is -29.11% for RXRX stock, with a simple moving average of -40.12% for the last 200 days.
Analysts’ Opinion of RXRX
Many brokerage firms have already submitted their reports for RXRX stocks, with Morgan Stanley repeating the rating for RXRX by listing it as a “Equal-Weight.” The predicted price for RXRX in the upcoming period, according to Morgan Stanley is $8 based on the research report published on May 22, 2023 of the previous year 2023.
Needham, on the other hand, stated in their research note that they expect to see RXRX reach a price target of $17. The rating they have provided for RXRX stocks is “Buy” according to the report published on March 16th, 2023.
KeyBanc Capital Markets gave a rating of “Overweight” to RXRX, setting the target price at $20 in the report published on September 16th of the previous year.
RXRX Trading at -40.77% from the 50-Day Moving Average
After a stumble in the market that brought RXRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.70% of loss for the given period.
Volatility was left at 7.13%, however, over the last 30 days, the volatility rate increased by 8.69%, as shares sank -35.66% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -43.69% lower at present.
During the last 5 trading sessions, RXRX fell by -27.02%, which changed the moving average for the period of 200-days by -54.75% in comparison to the 20-day moving average, which settled at $5.98. In addition, Recursion Pharmaceuticals Inc saw -37.28% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RXRX starting from Gibson Christopher, who sale 138,574 shares at the price of $6.04 back on Mar 27 ’25. After this action, Gibson Christopher now owns 1,117,450 shares of Recursion Pharmaceuticals Inc, valued at $836,987 using the latest closing price.
Gibson Christopher, the Officer of Recursion Pharmaceuticals Inc, proposed sale 138,574 shares at $6.04 during a trade that took place back on Mar 27 ’25, which means that Gibson Christopher is holding shares at $836,987 based on the most recent closing price.
Stock Fundamentals for RXRX
Current profitability levels for the company are sitting at:
- -8.15 for the present operating margin
- 0.11 for the gross margin
The net margin for Recursion Pharmaceuticals Inc stands at -7.88. The total capital return value is set at -0.38. Equity return is now at value -61.89, with -44.11 for asset returns.
Based on Recursion Pharmaceuticals Inc (RXRX), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -3.31. The debt to equity ratio resting at 0.1. The interest coverage ratio of the stock is -304.71.
Currently, EBITDA for the company is -426.72 million with net debt to EBITDA at 1.14. When we switch over and look at the enterprise to sales, we see a ratio of 20.22. The receivables turnover for the company is 1.2for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.81.
Conclusion
In a nutshell, Recursion Pharmaceuticals Inc (RXRX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
